lepodisiran

News

ACC25: Positive results with Lilly's Lp(a)-lowering drug

Eli Lilly's lepodisiran has been shown to reduce Lp(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial.

News

AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year

A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular

News

OpenBind unveils its first AI model for drug discovery

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks